Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ACIU 
AC Immune Ltd (ACIU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ACIU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.52
1 Year Target Price $9.52
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.15% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 202.21M USD | Price to earnings Ratio - | 1Y Target Price 9.52 |
Price to earnings Ratio - | 1Y Target Price 9.52 | ||
Volume (30-day avg) 4 | Beta 1.58 | 52 Weeks Range 1.43 - 4.26 | Updated Date 06/30/2025 |
52 Weeks Range 1.43 - 4.26 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -184.04% | Operating Margin (TTM) -1956.57% |
Management Effectiveness
Return on Assets (TTM) -17.07% | Return on Equity (TTM) -43.5% |
Valuation
Trailing PE - | Forward PE 11.24 | Enterprise Value 27292164 | Price to Sales(TTM) 7.15 |
Enterprise Value 27292164 | Price to Sales(TTM) 7.15 | ||
Enterprise Value to Revenue 0.77 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 100600000 | Shares Floating 39872326 |
Shares Outstanding 100600000 | Shares Floating 39872326 | ||
Percent Insiders 38.01 | Percent Institutions 26.12 |
Analyst Ratings
Rating 2 | Target Price 9.52 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
AC Immune Ltd
Company Overview
History and Background
AC Immune SA, founded in 2003 in Lausanne, Switzerland, is a clinical-stage biopharmaceutical company discovering, designing and developing therapeutic and diagnostic products for the prevention and treatment of diseases caused by misfolded proteins. It went public in 2016.
Core Business Areas
- Neurodegenerative Diseases: Focuses on therapies and diagnostics for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders related to protein misfolding.
- Antibody Discovery and Engineering: Developing proprietary SupraAntigen and Morphomer platforms for generating antibodies.
- Diagnostics: Developing diagnostic tools for early detection and monitoring of neurodegenerative diseases.
Leadership and Structure
Dr. Andrea Pfeifer is the CEO. The company has a Board of Directors overseeing strategic direction and management.
Top Products and Market Share
Key Offerings
- ACI-24.060 (anti-Abeta vaccine): A therapeutic vaccine targeting amyloid beta for Alzheimer's disease. Phase 2 clinical trials are ongoing. Market share is currently 0% as it is not yet approved. Competitors include Biogen (Aduhelm/Leqembi), Eli Lilly (donanemab), and Roche (gantenerumab).
- ACI-35.030 (anti-Tau vaccine): A therapeutic vaccine targeting pathological tau for Alzheimer's disease and other tauopathies. Currently in clinical development. Market share is currently 0% as it is not yet approved. Competitors include Eisai and Biogen (Alzheimer's).
- Crenezumab (partnered with Roche): An anti-Abeta antibody. While crenezumab failed in its primary endpoint, AC Immune continues to work with Roche on other products. Market share is effectively 0% as the product is not marketed. Competitors include Biogen (Aduhelm/Leqembi), Eli Lilly (donanemab).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with significant unmet needs in neurodegenerative diseases.
Positioning
AC Immune is positioned as a leader in developing immunotherapies for neurodegenerative diseases, particularly Alzheimer's and Parkinson's. Their competitive advantage lies in their proprietary technology platforms.
Total Addressable Market (TAM)
The global Alzheimer's disease market is expected to reach hundreds of billions USD. AC Immune aims to capture a significant share with its innovative therapies and diagnostics.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms (SupraAntigen and Morphomer)
- Strong scientific team and expertise in neurodegenerative diseases
- Partnerships with major pharmaceutical companies (e.g., Roche)
- Diverse pipeline of therapeutic and diagnostic candidates
Weaknesses
- High dependence on clinical trial outcomes
- High cash burn rate
- Product not yet in the market and therefore has zero revenue
- Competition from larger pharmaceutical companies
Opportunities
- Growing prevalence of neurodegenerative diseases
- Increasing demand for effective therapies and diagnostics
- Potential for breakthrough therapies with disease-modifying effects
- Expansion of partnerships and collaborations
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies
- Patent expirations
- Unsuccessful development of viable drug product candidate
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- RO.SW
Competitive Landscape
AC Immune faces strong competition from larger pharmaceutical companies with more resources. The company's strengths lie in its innovative technology platforms and specialized expertise.
Growth Trajectory and Initiatives
Historical Growth: AC Immune's growth has been driven by its pipeline advancement and strategic partnerships.
Future Projections: Future growth is dependent on successful clinical trial results and regulatory approvals. Analyst estimates vary significantly.
Recent Initiatives: Advancement of clinical programs, expansion of research and development capabilities, and securing new partnerships.
Summary
AC Immune is a clinical-stage company with innovative technology in neurodegenerative diseases but the company does not have any approved products at this time. It relies heavily on clinical trial success and partnerships. The company is a leader in its sector but is competing against bigger, well funded competitors. Investors should pay attention to clinical trial results and regulatory decisions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- AC Immune Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is approximate and based on available information. Clinical trial results are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AC Immune Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-09-23 | Co-Founder, CEO & Director Dr. Andrea Pfeifer Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 133 | Website https://www.acimmune.com |
Full time employees 133 | Website https://www.acimmune.com | ||
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.